Total Payments
$3,290
2024 Payments
$41.54
Companies
29
Transactions
194
Medicare Patients
859
Medicare Billing
$153,261
Payment Breakdown by Category
Food & Beverage$3,263 (99.2%)
Other$27.42 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,263 | 193 | 99.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $27.42 | 1 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $699.87 | 43 | $0 (2023) |
| GRT US Holding, Inc. | $406.33 | 31 | $0 (2022) |
| Boston Scientific Corporation | $222.53 | 16 | $0 (2023) |
| Lundbeck LLC | $209.12 | 9 | $0 (2024) |
| Scilex Pharmaceuticals Inc. | $200.16 | 10 | $0 (2023) |
| Medtronic, Inc. | $182.56 | 2 | $0 (2023) |
| Abbott Laboratories | $176.27 | 14 | $0 (2022) |
| Forte Bio-Pharma LLC | $168.93 | 9 | $0 (2023) |
| Collegium Pharmaceutical, Inc. | $147.35 | 9 | $0 (2023) |
| Amgen Inc. | $129.45 | 8 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $41.54 | 2 | Indivior Inc. ($21.47) |
| 2023 | $848.56 | 38 | ABBVIE INC. ($275.75) |
| 2022 | $930.64 | 52 | ABBVIE INC. ($285.96) |
| 2021 | $1,469 | 102 | GRT US Holding, Inc. ($330.76) |
All Payment Transactions
194 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: OUD | ||||||
| 05/06/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.07 | General |
| Category: NEUROLOGY | ||||||
| 09/15/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $12.96 | General |
| Category: PAIN | ||||||
| 08/23/2023 | Forte Bio-Pharma LLC | PROLATE (Drug), NALOCET, PROLATE | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: PAIN | ||||||
| 08/22/2023 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: General - Pain Management_NMD | ||||||
| 08/22/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $16.35 | General |
| Category: Opioid Analgesic | ||||||
| 08/08/2023 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 08/07/2023 | Brainsway USA INC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $27.42 | General |
| 07/28/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $8.92 | General |
| Category: PAIN | ||||||
| 07/27/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 07/20/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: NEUROSCIENCE | ||||||
| 07/14/2023 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $168.28 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 07/12/2023 | Amneal Pharmaceuticals LLC | LYVISPAH (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: NEUROLOGY | ||||||
| 06/28/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: NEUROSCIENCE | ||||||
| 06/22/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: PAIN | ||||||
| 06/17/2023 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: NEUROSCIENCE | ||||||
| 06/13/2023 | SPR Therapeutics, Inc | SPRINT PNS System (Device) | Food and Beverage | Cash or cash equivalent | $22.96 | General |
| Category: Pain management | ||||||
| 06/07/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $15.40 | General |
| Category: Opioid Analgesic | ||||||
| 06/01/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $15.43 | General |
| Category: PAIN | ||||||
| 05/31/2023 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/26/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: NEUROSCIENCE | ||||||
| 05/15/2023 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $18.74 | General |
| Category: Opioid Analgesic | ||||||
| 04/20/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $24.84 | General |
| Category: NEUROSCIENCE | ||||||
| 04/20/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Analgesic | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 138 | 326 | $173,501 | $17,804 |
| 2022 | 4 | 199 | 621 | $276,769 | $36,300 |
| 2021 | 4 | 222 | 774 | $350,256 | $52,382 |
| 2020 | 4 | 300 | 878 | $352,638 | $46,776 |
Total Patients
859
Total Services
2,599
Medicare Billing
$153,261
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 174 | $77,528 | $7,751 | 10.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 46 | 103 | $70,147 | $6,966 | 9.9% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 22 | 25 | $22,657 | $2,804 | 12.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 21 | 24 | $3,169 | $284.05 | 9.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 72 | 340 | $190,400 | $21,999 | 11.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 186 | $69,564 | $8,996 | 12.9% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 32 | 41 | $11,729 | $4,632 | 39.5% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 44 | 54 | $5,076 | $672.33 | 13.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 73 | 471 | $263,760 | $35,089 | 13.3% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 54 | 79 | $22,600 | $8,950 | 39.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 47 | 153 | $57,222 | $7,448 | 13.0% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2021 | 48 | 71 | $6,674 | $894.60 | 13.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 89 | 323 | $180,422 | $21,300 | 11.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 96 | 393 | $143,366 | $16,105 | 11.2% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2020 | 56 | 72 | $20,597 | $8,239 | 40.0% |
| 80305 | Testing for presence of drug | Office | 2020 | 59 | 90 | $8,253 | $1,133 | 13.7% |
About Ashley Homan, ARNP
Ashley Homan, ARNP is a Registered Nurse healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/23/2015. The National Provider Identifier (NPI) number assigned to this provider is 1033506415.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ashley Homan, ARNP has received a total of $3,290 in payments from pharmaceutical and medical device companies, with $41.54 received in 2024. These payments were reported across 194 transactions from 29 companies. The most common payment nature is "Food and Beverage" ($3,263).
As a Medicare-enrolled provider, Homan has provided services to 859 Medicare beneficiaries, totaling 2,599 services with total Medicare billing of $153,261. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Registered Nurse
- Other Specialties Family, Nurse Practitioner
- Location Omaha, NE
- Active Since 04/23/2015
- Last Updated 07/21/2022
- Taxonomy Code 163W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1033506415
Products in Payments
- QULIPTA (Drug) $350.86
- Qutenza (Drug) $297.33
- UBRELVY (Drug) $252.17
- VYEPTI (Biological) $209.12
- INTELLIS ADAPTIVESTIM (Device) $182.56
- ZTLido (Drug) $150.37
- NURTEC ODT (Drug) $149.72
- XTAMPZA (Drug) $133.74
- Aimovig (Biological) $129.45
- BOTOX (Biological) $96.84
- RELISTOR (Drug) $87.36
- Proclaim IPG (Device) $87.35
- NALOCET (Drug) $76.44
- MOVANTIK (Drug) $70.50
- Superion (Device) $65.13
- Nalu Neurostimulation System (Device) $62.08
- WAVEWRITER ALPHA (Device) $50.73
- NT1100 NT2000iX Simplicity (Device) $49.09
- NAPRELAN (Drug) $48.39
- AJOVY (Biological) $48.29
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Registered Nurse Doctors in Omaha
Angela Craig, Aprn, APRN
Registered Nurse — Payments: $34,288
Registered Nurse $34,288
Jasper Kaufman, Aprn, APRN
Registered Nurse — Payments: $8,208
Registered Nurse $8,208
Margaret Wallace, Aprn, APRN
Registered Nurse — Payments: $5,778
Registered Nurse $5,778
Rise Mitchell, Dnp, Aprn, Pmhnp-Bc, DNP, APRN, PMHNP-BC
Registered Nurse — Payments: $4,373
Registered Nurse $4,373
Rebecca Andresen, Rn, RN
Registered Nurse — Payments: $4,162
Registered Nurse $4,162
Karen Betjacob, Aprn, APRN
Registered Nurse — Payments: $3,550
Registered Nurse $3,550